Due to the continuous increase in the number of patients of Kovid-19, most of the hospitals in the country are now fully filled. Even severely afflicted patients have to wait a long time. Are there any measures that can reduce the risk of hospitalization of patients? Researchers at the University of Oxford have described one such remedy which can save the life of patients. According to a study conducted by the university, a common drug used to treat asthma can be helpful in curing patients with Kovid-19 rapidly.
In a study published in the Lancet Journal, researchers have reported that giving glucocorticoids via breath may benefit kovid patients. Not only this, but its use also reduces the risk of hospitalization of patients.
Similarly, China, Italy, and other countries reported in their studies that patients with asthma and chronic obstructive pulmonary disease (COPD) were less likely to be hospitalized. This is because these patients are already advised to take this medicine through an inhaler.
This Lancet study included 146 participants from the UK. Half of these people were asked to take a drug called bideonide via inhalers. The team of researchers found that the treatment of kovid became easier for people taking biodonide for a short period of time. Not only this, but it can also be beneficial in the treatment of sufferers from Kovid severely.
In addition, it was found by the experts that in the patients of Kovid who took biodonide, fever was also reported less than others. Apart from this, a better improvement in symptoms of Kovid was also observed within 14 days in such patients. Based on this study, it can be said that some medicines given to asthma patients during Kovid-19 may be beneficial.